Hjem › Akut bifænotypisk leukæmi › Tennessee
Akut bifænotypisk leukæmi kliniske forsøg i Tennessee
10 studier for Akut bifænotypisk leukæmi søger deltagere på steder i Tennessee.
Byer i Tennessee
Officiel studietekst (engelsk)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
- The Children's Hospital at TriStar Centennial, Nashville
- og 1 flere
RekruttererFase 2
365 Days · Alle køn · Opdateret 25. sep. 2026 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- T C Thompson Children's Hospital, Chattanooga
- East Tennessee Childrens Hospital, Knoxville
- The Children's Hospital at TriStar Centennial, Nashville
- og 1 flere
RekruttererFase 3
365 Days – 25 Years · Alle køn · Opdateret 25. aug. 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
- The Children's Hospital at TriStar Centennial, Nashville
- og 1 flere
RekruttererFase 1/2
Op til 22 år · Alle køn · Opdateret 25. aug. 2026 · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- St. Jude Children's Research Hospital, Memphis
RekruttererFase 2
Alder 1 til 18 · Alle køn · Opdateret 10. aug. 2026 · NCT06390319Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- St. Jude Children's Research Hospital, Memphis
RekruttererFase 1
Alder 1 til 30 · Alle køn · Opdateret 3. aug. 2026 · NCT06177067Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
- St. Jude Children's Research Hospital, Memphis
RekruttererFase 4
Alder 1 til 18 · Alle køn · Opdateret 14. jul. 2026 · NCT06289673Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Vanderbilt University, Ingram Cancer Center, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 7. jul. 2026 · NCT07216443The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
RekruttererFase 1/2
Alder 12 til 95 · Alle køn · Opdateret 15. apr. 2026 · NCT04329728Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- St. Jude Children's Research Hospital, Memphis
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. dec. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.